Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1897 views | HTML 3222 views | ?
Mehdi Farshchian1,2, Liisa Nissinen1,2, Elina Siljamäki1,2, Pilvi Riihilä1,2, Minna Piipponen1,2, Atte Kivisaari1,2, Markku Kallajoki3, Reidar Grénman4, Juha Peltonen5, Sirkku Peltonen1, Koen D. Quint6,7, Jan Nico Bouwes Bavinck6 and Veli-Matti Kähäri1,2
1Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland
2MediCity Research Laboratory, University of Turku, Turku, Finland
3Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland
4Department of Otorhinolaryngology - Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland
5Department of Cell Biology and Anatomy, University of Turku, Turku, Finland
6Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
7DDL Diagnostic Laboratory, Rijswijk, The Netherlands
Veli-Matti Kähäri, email: [email protected]
Keywords: skin, cancer, inflammasome, AIM2, keratinocyte
Received: June 29, 2016 Accepted: April 18, 2017 Published: May 02, 2017
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer. Inflammation is a typical feature in cSCC progression. Analysis of the expression of inflammasome components in cSCC cell lines and normal human epidermal keratinocytes revealed upregulation of the expression of AIM2 mRNA and protein in cSCC cells. Elevated levels of AIM2 mRNA were noted in cSCCs in vivo compared with normal skin. Strong and moderate tumor cell specific expression of AIM2 was detected with immunohistochemistry (IHC) in sporadic human cSCCs in vivo, whereas expression of AIM2 was moderate in cSCC in situ (cSCCIS) and low or absent in actinic keratosis (AK) and normal skin. IHC of cSCCs, cSCCIS and AKs from organ transplant recipients also revealed strong and moderate tumor cell specific expression of AIM2 in cSCCs. Knockdown of AIM2 resulted in reduction in viability of cSCC cells and onset of apoptosis. RNA-seq and pathway analysis after knockdown of AIM2 in cSCC cells revealed downregulation of the biofunction category Cell cycle and upregulation of the biofunction category Cell Death and Survival. Knockdown of AIM2 also resulted in reduction in invasion of cSCC cells and downregulation in production of invasion proteinases MMP1 and MMP13. Knockdown of AIM2 resulted in suppression of growth and vascularization of cSCC xenografts in vivo. These results provide evidence for the role of AIM2 in the progression of cSCC and identify AIM2 inflammasome function as a potential therapeutic target in these invasive and metastatic tumors.
Keratinocyte-derived cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer and its incidence is increasing due to aging of population and increased recreational exposure to the sunlight [1-3]. Cumulative lifetime sun exposure is an important risk factor for cSCC and other risk factors include chronic ulcers, chronic inflammation of the skin, and immunosuppression [4, 5]. The progression of actinic keratosis (AK) to cSCC in situ (cSCCIS) and invasive cSCC is associated with inflammation . Changes in the microenvironment of the premalignant skin lesion, such as alteration of the composition of the epidermal basement membrane and dermal extracellular matrix, and accumulation of inflammatory cells and microbial structures, are possible mechanisms for the role of inflammation in progression of AK to cSCC . On the other hand, cSCCs in immunosuppressed patients progress rapidly and have been reported to be associated with higher rate of recurrence, metastasis, and mortality [8-10].
Inflammasomes are important components of the innate immune response involved in onset of inflammation. Inflammasomes serve as sensors for exogenous and endogenous danger signals and trigger activation and secretion of interleukin (IL)-1β and IL-18 . Inflammasomes contain 1) a scaffold and sensor protein, either a Nod-like receptor (NLRP1, NLRP3, NLRC4, and NLRP6), or a HIN (hematopoietic IFN inducible nuclear antigen) domain protein, AIM2 (absent in melanoma 2) or IFI16 (IFN-γ-inducible protein 16), 2) adaptor protein ASC (apoptosis associated speck-like protein containing a CARD), and 3) effector protein caspase-1 . The HIN-200 domain of AIM2 and IFI16 serves as a sensor for cytoplasmic double stranded DNA and the pyrin domain interacts with ASC for activation of caspase-1 [13, 14]. Inflammasome function has mainly been characterized in immune cells, but NLRP1, NLRP3, and AIM2 inflammasomes have also been found in epidermal keratinocytes . AIM2 inflammasome has been shown to be involved in the pathogenesis of autoimmune disorders, including psoriasis and systemic lupus erythematosus [13, 16, 17]. In addition, the role of inflammasome activation in autoinflammatory disorders has recently been emphasized .
Here, we have examined the role of inflammasome in the progression of cSCC. We show, that the expression of AIM2 is specifically upregulated in cSCC cells in culture and in tumor cells in cSCCs of immunocompetent individuals and organ transplant recipients (OTRs) in vivo. In addition, AIM2 knockdown results in reduction in cSCC cell viability and invasion, and suppression of growth and vascularization of cSCC xenografts in vivo. These results provide evidence for the role of AIM2 in the progression of cSCC and identify AIM2 inflammasome function as a potential therapeutic target in recurrent and metastatic cSCCs.
Upregulation of AIM2 expression in cSCC cells
The expression of mRNAs for inflammasome components in primary (n=5) and metastatic (n=3) cSCC cell lines and normal human epidermal keratinocytes (NHEKs) from 5 individuals was analyzed using RNA-seq. The expression of molecules involved in pathways related to innate immunity (KEGG pathways: Cytosolic DNA-sensing, NOD-like receptor signaling, RIG-I-like receptor signaling) in NHEKs and cSCC cells is shown in Supplementary Figure 1. These results showed specific upregulation of AIM2 mRNA expression in cSCC cells, as compared to NHEKs (Supplementary Figure 1A, 1B). Significantly elevated levels of AIM2 mRNA were also noted in cSCC cell lines with quantitative real-time PCR (qRT-PCR), whereas the expression level was very low in NHEKs (Figure 1A). The mean level of AIM2 mRNA expression was also significantly higher in RNA from cSCC tumors (n=6) compared with normal skin (n=6) in vivo (Figure 1B).
Figure 1: Upregulation of AIM2 expression in cSCC cells. (A) AIM2 mRNA levels in primary (n=5) and metastatic (n=3) human cSCC cell lines and in NHEKs (n=5) were determined with qRT-PCR. (B) AIM2 mRNA levels in cSCC tumors (n=6) and normal human skin (n=6) in vivo were analyzed by qRT-PCR. (C) AIM2 protein levels in cell lysates of NHEKs and cSCC cells were analyzed by Western blotting with β-actin as a marker for loading. Level of AIM2 was quantitated by densitometry and corrected for the level of β-actin. (D) Indirect immunofluorescence staining was used to localize AIM2 and β-Actin in the cSCC cells and NHEKs. Nuclei were visualized with Hoechst staining. Scale bar=10 μm. (**P<0.01; Mann-Whitney two-way U-test).
Production of AIM2 by cSCC cell lines and NHEKs was analyzed by Western blotting of the cell lysates. A specific 38 kDa band corresponding to AIM2 was detected in all cSCC cell lines, whereas production of AIM2 protein in NHEKs was very low (Figure 1C). Immunofluorescence (IF) staining of permeabilized cSCC cells and NHEKs for AIM2 revealed abundant perinuclear expression of AIM2 in cSCC cells, whereas only weak labeling for AIM2 was noted in NHEKs (Figure 1D).
No significant difference in IFI16 mRNA levels was noted between cSCC cell lines and NHEKs (Supplementary Figure 2A), or between cSCC tumors in vivo and normal skin by qRT-PCR (Supplementary Figure 2B). Production of IFI16, adaptor protein ASC and caspase-1 was noted both in NHEKs and in cSCC cells (Supplementary Figure 2C). Based on the specific upregulation of AIM2 expression in cSCC cells, it was selected for further characterization in cSCC.
Overexpression of AIM2 by tumor cells in sporadic and organ transplant recipients cSCCs in vivo
To analyze the expression of AIM2 in vivo, tissue microarrays (TMAs) consisting of normal skin (n=15), UV-induced premalignant lesions (AK) (n=71), cSCCIS (n=60), and cSCCs (n=81) were analyzed by immunohistochemistry (IHC). In normal skin, expression of AIM2 was absent (-) (67%) or weak (+) (33%) (Figure 2A, 2G). Epidermal layer of AK was mainly weakly positive (+) for AIM2 in the majority of samples (69%) (Figure 2B, 2G). In cSCCIS, cytoplasmic AIM2 expression level was mainly moderate (++) (58%) (Figure 2C, 2G). In invasive cSCCs, cytoplasmic and perinuclear AIM2 was noted in tumor cells in the invasive margin and the expression was mainly strong (+++) (38%) (Figure 2D, 2E, 2G) or moderate (49%). AIM2 expressing tumor cells were located at the invasive edges of the cSCC tumor (Supplementary Figure 3). In whole tumor sections of cSCC, AIM2 expression was seen in tumor cells, but the adjacent normal skin was negative or weak for AIM2 (Supplementary Figure 4). Semiquantitative analysis revealed significantly more abundant AIM2 expression in sporadic cSCCs compared with cSCCIS, AKs and normal skin (Figure 2G). In addition, AIM2 expression in cSCCIS was significantly more abundant than in AKs (Figure 2G). AIM2 expression was also analyzed in whole tumor sections of AK (n=58), cSCCIS (n=59) and cSCC (n=57) of OTRs by IHC. Tumor cell-specific cytoplasmic and perinuclear AIM2 expression was noted in all cSCCs (Figure 2F). Semiquantitative analysis of the AIM2 expression (Figure 2H) revealed strong (+++) (Figure 2F) (51%) and moderate (++) (49%) AIM2 expression in cSCC of OTRs. AIM2 expression level was significantly stronger in cSCC compared with cSCCIS and AK in OTRs (Figure 2H).
Figure 2: Expression of AIM2 by tumor cells in sporadic and organ transplant recipient (OTR) cSCCs in vivo. (A-E) AIM2 expression was determined by IHC of TMAs containing normal human skin (n=15), actinic keratosis (AK) (n=71), cSCCs in situ (cSCCIS) (n=60) and sporadic cSCCs (n=81). In sporadic, UV-induced human cSCC tumor cell-specific cytoplasmic and perinuclear localization of AIM2 was detected and the expression level was mainly strong (+++) (D, E) or moderate (++). In cSCCIS, AIM2 expression level was moderate (++) (C) in the majority of sections. In AK, AIM2 expression was mainly weak (+) (B). AIM2 expression was absent (-) or weak (+) (A) in normal skin samples. (F) Tumor cell-specific cytoplasmic and perinuclear expression of AIM2 was detected in cSCCs of OTRs. Scale bar=50 μm. (G) AIM2 expression level was significantly stronger in sporadic cSCCs compared with cSCCIS, AK and normal skin. (H) In OTR derived tissues, AIM2 expression was significantly more abundant in cSCC (n=57) compared with cSCCIS (n=59) and AK (n=58). (*P<0.05, *** P<0.001; Fisher’s exact test).
Alteration of gene expression profile in cSCC cells after AIM2 knockdown
To examine the functional role of AIM2 in cSCC cells, two specific siRNAs were used to knock down the expression of AIM2 (Figure 3A). RNA-seq analysis was performed after AIM2 knockdown of three cSCC cell lines. Pathway analysis of the genes significantly regulated following AIM2 knockdown revealed significant downregulation of the biofunction category Cell Cycle and upregulation of biofunction category Cell Death and Survival (Figure 3B). Among the top molecular networks regulated after AIM2 knockdown were Cell Death and Survival, Cellular Development, Organismal Development (score=32) and Cell cycle, cellular assembly and organization, DNA replication, recombination, and repair (score=24; Supplementary Table 1). In addition, the genes significantly regulated following AIM2 knockdown were associated with GO terms including Degradation of extracellular matrix and KEGG pathways like ECM-receptor interaction (Figure 3C). Analysis of Cell cycle, cellular assembly and organization, DNA replication, recombination, and repair as one of the top molecular networks regulated after AIM2 knockdown revealed downregulation of the expression of several cell cycle related genes: CDK1, CDC7, CCNA1, CCNB3, KIF11, and TTK (Figure 3D). Cdk1 is a key player in cell cycle regulation, which has been shown to be able to bind all mammalian cyclins and to be sufficient to drive cell cycle . Downregulation of Cdk1 after AIM2 siRNA knockdown was detected both at mRNA and protein level (Figure 3E).
Figure 3: Alteration of gene expression profile in cSCC cells afterAIM2 knockdown. (A) cSCC cells (UT-SCC7) were transfected with AIM2 siRNA_5, AIM2 siRNA_6, or control siRNA (CsiRNA) (75 nM) and transfection efficiency was examined by Western blotting 72 hours after transfection. β–Actin was used as a marker for equal loading. (B-E) Three cSCC cell lines (UT-SCC7, UT-SCC12A, and UT-SCC105) were transfected with AIM2 siRNA_6 or control siRNA. 72 hours after transfection, whole transcriptome analysis was performed with RNA-seq. Summary of (B) Ingenuity pathway analysis (IPA) biofunctions and (C) gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to AIM2 knockdown (P < 0.05, FC log2 > 0.75). (D) Molecular interactions involved in the network Cell cycle, cellular assembly and organization, DNA replication, recombination, and repair as one of the top networks regulated after AIM2 knockdown in cSCC cells (score=24; Supplementary Table 1) are depicted with IPA (P<0.05 and fold change (FC) (log2) >0.75). Red color indicates up-regulation, and green color indicates down-regulation. The intensity of the color shows the magnitude of FC. The arrows and the lines show the interactions (solid line indicated direct and dashed line indirect interaction). (E) Normalized CDK1 mRNA expression was determined from cSCC cells with RNA-seq after AIM2 siRNA_6 knockdown (left panel). UT-SCC7 cells were transfected with AIM2 siRNA_5, AIM2 siRNA_6, or control siRNA (75 nM) and expression of Cdk1/Cdk2 was determined by Western blotting 72 hours after transfection with siRNAs. Level of Cdk1/Cdk2 was quantitated by densitometry and corrected for the level of β–Actin used as a marker for equal loading (right panel).
Knockdown of AIM2 results in reduced cell viability and invasion
To further explore the functional role of AIM2 in cSCC cells, expression of AIM2 was knocked down with two specific siRNAs (Figure 3A). Analysis of cell viability revealed significant reduction in the number of viable cSCC cells 24, 48, and 72 hours after transfection with AIM2 siRNA compared with control siRNA transfected cells (Figure 4A and Supplementary Figure 5). The experiment was repeated with three different cSCC cells lines with similar results (data not shown). In addition, the number of cSCC cells was significantly decreased 72 hours after AIM2 siRNA transfection, as compared with the cells transfected with control siRNA (Supplementary Figure 6). Increased number of TUNEL positive cells, as a sign for apoptosis was also detected 48 hours after AIM2 siRNA transfection, as compared with control siRNA transfected cells (Figure 4B). Potent inhibition of cSCC cell invasion through collagen was noted 72 hours after transfection of the cSCC cells with the AIM2 siRNA, as compared with the control siRNA transfected cSCC cells (Figure 4C). This experiment was repeated with two cSCC cells lines with similar results (data not shown). Production of MMP13 and MMP1, two collagenolytic invasion proteinases associated with the invasion of cSCC cells, was notably inhibited 72 hours after AIM2 knockdown in cSCC cells both at mRNA (Figure 4D) and protein level (Figure 4E and Supplementary Figure 7).
Figure 4: Knockdown of AIM2 inhibits viability and invasion of cSCC cells. (A) The number of viable cSCC cells (UT-SCC7) was determined 24, 48, and 72 hours after transfection with AIM2 siRNA_6 and control siRNA (CSiRNA) (75 nM) (mean ± SD, n=8). (B) cSCC cells (UT-SCC7) were transfected with AIM2 siRNA_6, or control siRNA and 48 hours after transfection apoptotic cells were detected with TUNEL staining and the relative number of TUNEL positive apoptotic cells with positive nuclear staining was determined by counting 2000-3000 cells at 10× magnification per image (n=3, mean ± SD) (left panel). Representative images of the quantification are shown. Scale bar=100 μm (right panel). (C) UT-SCC7 cell lines were transfected with AIM2 or control siRNAs and seeded to the inserts coated with type I collagen 24 hours after transfection. After 48 hours the number of invaded cells was counted (mean ± SD, n=3). (D) MMP13 and MMP1 mRNA levels were determined by qRT-PCR 72 hours after AIM2 knockdown in cSCC cells. (E) Levels of MMP13 and MMP1 in conditioned media of cSCC cells (UT-SCC12A) were determined by Western blot analysis 72 hours after AIM2 knockdown. TIMP1 was used as a marker for equal loading. Levels of MMP1 and MMP13 were quantitated by densitometry and corrected for the level of TIMP1. (*P<0.05, ***P<0.001; Student’s t-test).
Knockdown of AIM2 results in suppression in growth and vascularization of human cSCC xenografts
The role of AIM2 in growth of the cSCC tumors in vivo was examined in xenograft model. Metastatic cSCC cells (UT-SCC7) (5×106) were transfected with AIM2 siRNA or control siRNA, incubated for 72 hours and injected subcutaneously into the back of SCID mice. Significant suppression in growth of the xenograft tumors was noted in AIM2 siRNA group compared with the control siRNA group (Figure 5A, 5B). Histological analysis of the xenografts harvested 21 days after the implantation revealed, that tumors in AIM2 siRNA group were less cellular compared with xenografts in control siRNA group (Figure 5B). IHC analysis of the tumors for proliferation marker Ki-67 showed significantly lower number of proliferating cells in the xenografts established with cSCC cells transfected with AIM2 siRNA (21%) compared with control siRNA tumors (70%) (Figure 5B, 5C). Analysis of the vasculature of the xenografts using IHC for vascular marker CD34 revealed significantly reduced number of CD34-positive blood vessels in AIM2 knockdown tumors compared with the controls (Figure 5B, D).
Figure 5: AIM2 knockdown suppresses growth and vascularization of human cSCC xenografts. (A) cSCC cells (UT-SCC7) were transfected with AIM2 siRNA_6 or control siRNA (75 nM). 72 hours after transfection, cells (5×106) were injected subcutaneously into the back of SCID mice (n=8 for each group) and the size of tumors was measured twice a week (mean ± SEM). (B) Tumors were harvested after 21 days, embedded in paraffin and stained with H&E (upper panels), for proliferation marker Ki-67 (middle panels), and for vascular endothelial marker CD34 (lower panels). (C) The percentages of Ki-67-positive tumor cells in xenografts were counted (mean ± SEM). (D) The density of CD34-positive blood vessels in xenografts was determined in each tumor. Scale bar=100μm (*P<0.05, **P<0.01, ***P<0.001; Student’s t-test).
There is increasing evidence that chronic inflammation is associated with cancer progression [19, 20]. Chronic inflammation has been recognized as a risk factor for cSCC  and inflammation is a typical feature of the progression of AK lesions to invasive and metastatic cSCC . Inflammasomes are important components of the innate immune response involved in the onset of inflammation. Inflammasome component AIM2 serves as a sensor for cytoplasmic double-stranded DNA, and this way plays a key role in response to bacterial and viral colonization . Activation of inflammasome by cytoplasmic DNA in epidermal keratinocytes can promote initiation of inflammation in autoimmune and autoinflammatory skin diseases [13, 15, 22].
There is recent evidence for the involvement of AIM2 in carcinogenesis, but the exact role of AIM2 in cancer progression remains unclear. In colorectal cancer AIM2 appears to play a protective role as lack of AIM2 expression is associated with cancer progression, metastasis, and less favorable prognosis . On the other hand, restoration of AIM2 has been shown to stimulate invasion of colorectal cancer cells . Overexpression of AIM2 has been shown to suppress proliferation of breast cancer cells and growth of xenografts . Elevated expression level of AIM2 in senescent prostate epithelial cells is associated with increased IL-1β production and development of benign prostatic hyperplasia, whereas the expression of AIM2 in prostate cancer cells is low .
Here, we have examined the role of AIM2 in the progression of cSCC. Our results show that the expression of AIM2 is specifically upregulated in primary and metastatic cSCC cell lines compared with NHEKs using RNA-seq technique and qRT-PCR. Analysis of the AIM2 mRNA expression level by qRT-PCR revealed upregulation of AIM2 mRNA also in cSCC tumors in vivo compared with normal skin. In addition, markedly higher level of AIM2 protein in cSCC cell lines compared with NHEKs were detected with Western blot analysis and IF staining.
Analysis of a large panel of tissue samples from normal skin, AK, cSCCIS, and sporadic cSCCs by IHC revealed tumor cell specific expression for AIM2 in cSCCs. In accordance with previous observations, the cellular localization of AIM2 was cytoplasmic and perinuclear [27, 28]. In the majority of cSCCs, the level of AIM2 expression was strong or moderate and although the majority of the cSCCIS lesions showed moderate AIM2 expression, a trend towards strong expression was noted. Expression of AIM2 was mainly weak or absent in AKs and normal skin. Analysis of cSCCs, cSCCIS and AKs of OTRs with IHC revealed strong and moderate tumor cell specific AIM2 expression in cSCCs. The majority of AK lesions of OTRs were negative for AIM2, whereas in cSCCIS the expression of AIM2 was mainly moderate or weak. Altogether, these results show that the expression of AIM2 is very low in normal intact skin and that it is specifically induced in tumor cells in cSCCs suggesting AIM2 as a biomarker for the progression of premalignant lesions toward invasive cSCC.
Knockdown of AIM2 expression in cSCC cells resulted in significant suppression in the growth of cSCC xenografts compared with tumors in the control siRNA group. Furthermore, AIM2 knockdown resulted in marked reduction in vascularization of the xenografts. Together these findings provide evidence for the role of AIM2 in cSCC growth. Functional studies with cSCC cells showed, that knockdown of AIM2 resulted in reduction in viability and increase in the number of apoptotic cells. Furthermore, silencing of AIM2 expression resulted in decreased invasion of cSCC cells in culture associated with reduction in the production of MMP13 and MMP1, two collagenolytic MMPs associated with cSCC invasion [29, 30]. It is therefore possible, that reduction in MMP13 and MMP1 production after AIM2 knockdown impairs implantation of cSCC cells in the skin of SCID mice and this way results in delay in tumor growth.
The molecular basis for the role of AIM2 in the growth of cSCCs was elucidated by RNA-seq analysis of cSCC cells after AIM2 knockdown. Pathway analysis of the gene expression profile following AIM2 knockdown revealed significant downregulation of the biofunction M phase in the category Cell Cycle and upregulation of the biofunction related to category Cell Death and Survival. In addition, downregulation of the expression of several genes coding for proteins regulating cell cycle, including CDK1, CDC7, CCNA1, CCNB3, KIF11, and TTK in the network Cell cycle, cellular assembly and organization, DNA replication, recombination, and repair, was noted following AIM2 knockdown. Cdk1 is a key player in cell cycle regulation and has been shown to be sufficient to drive cell cycle . These observations provide mechanistic evidence, that AIM2 is involved in regulation of the viability of cSCC cells and may this way promote growth of cSCC. It is possible, that this effect is mediated indirectly by cytokines released by cSCC cells in response to activation of AIM2 inflammasome. Further studies using AIM2 knock-in are required to elucidate the biological function of AIM2 in cSCC cell growth.
Taken together, our findings revealed specific upregulation of AIM2 expression in cSCC cells in culture and in vivo. These results are in accordance with a recent study reporting AIM2 expression in a limited number of cSCCs . Our results also elucidated the role of AIM2 in the progression of sporadic cSCCs and cSCCs in OTRs, a specific population of immunosuppressed patients at risk for developing multiple cSCCs . Knockdown of AIM2 resulted in suppression of cSCC growth in vivo and in reduced viability and invasion of cSCC cells in culture. Small molecule inhibitors and antibodies are currently being studied to target inflammasome components for the cancer therapy . The results of the present study suggest AIM2 as a putative therapeutic target in cSCCs, in patients with unresectable, recurrent, or multiple tumors, and in patients with high risk for cSCC, e.g. immunosuppressed patients.
MATERIALS AND METHODS
Approval for use of tissue specimens and the collection of normal skin and SCC tissues was obtained from the Ethics Committee of the Hospital District of Southwest Finland, Turku, Finland and from the Leiden University Medical Center (LUMC), Leiden, the Netherlands. The study was performed in accordance with the ethical guidelines of the Declaration of Helsinki. Each patient gave their informed consent. The experiments with mice were approved by the State Provincial Office of Southern Finland and conducted according to institutional guidelines.
Human cSCC cell lines (n=8) were established from surgically removed SCCs of skin . Five cSCC cell lines were derived from primary cSCCs (UT-SCC12A, -91, -105, -111, and -118) and three from metastatic cSCCs (UT-SCC7, -59A, and -115). Authentication of the cell lines was performed by STR DNA profiling . NHEKs were cultured from healthy skin of individuals undergoing surgery for mammoplasty (n=4)  or purchased from PromoCell (n=1) (Heidelberg, Germany). NHEKs and cSCC cells were cultured as previously described .
For RNA extraction, samples of cSCCs (n=6) were obtained in Turku University Hospital from surgery of primary tumors and samples of normal skin (n=6) were obtained from mammoplastic surgery . TMAs consisting of samples from normal sun-protected skin (n=15), AK (n=71), cSCCIS (n=60), and UV-induced cSCC (n=81) were generated from the archival paraffin blocks of the Department of Pathology, Turku University Hospital [34-37]. Whole tumor sections of AK (n=58), cSCCIS (n=59) and cSCC (n=57) of immunosuppresed OTRs were obtained in the Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands.
Gene expression profiling
RNA and cDNA preparation were performed as previously described [35, 36]. Total RNA for RNA-seq was isolated from cells using miRNAeasy Mini kit (Qiagen, Chatsworth, CA). The Whole Transcriptome Analysis (SOLiD™, Applied Biosystems, Foster City, CA) was performed as described previously (accession number GSE66412) . RNA-seq was performed with RNAs derived from cSCC cell lines (n=3) 72 hours after AIM2 siRNA transfection using Illumina RNA-sequencing (Illumina Inc., San Diego, CA, USA) at Finnish Microarray and Sequencing Centre, Turku Center for Biotechnology. The samples were sequenced with the HiSeq2500 instrument using single-end sequencing chemistry with 50 bp read length and aligned against the human reference genome (hg19 assembly). Pathway analysis was performed with Ingenuinity Pathway Analysis (Ingenuity Systems, Redwood City, Redwood City, CA). P<0.05 and fold change (log2) >0.75 were used as thresholds in data analysis. RNA-seq data (accession number GSE94270) have been deposited in the public database GEO (Gene Expression Omnibus, NCBI; http://www.ncbi.nlm.nih.gov/geo/).
Levels of mRNA of AIM2, IFI16, MMP13 and MMP1 mRNA were determined with qRT-PCR using Applied Biosystems 7900HT Fast Real-Time PCR System [37, 38] and specific probes and primers (Oligomer, Finland) as follows:
AIM2 forward primer 5’-GGCCCAGCAGGAA TCTATCAG-3’
AIM2 reverse primer 5’-GAAGGGCTTCTTTGC TTTCAGTAC-3’
AIM2 probe 5’-Fam-AAGGGTTTCAGAAGCGCT GTTTGCC-Tamra-3’
IFI16 forward primer 5’- TCCTCAGATGCCTC-CATCAAC-3’
IFI16 reverse primer 5’- CAGGTTCAGTCTTCA-GTCTTGGT-3’
IFI16 probe 5’-Fam- CCAAGCAGCAGTTTCTT AACCACGT-Tamra-3’
Primers and probes for MMP13 and MMP1 have been described previously . Level of β-actin mRNA was used as control .
Western blot analysis
Production of AIM2 in cSCC cell lines and NHEKs was determined by Western blotting using anti-AIM2 antibody (Abnova, Walnut, CA, USA) as previously described . Levels of MMP1 and MMP13 in conditioned media were determined by Western blotting using anti-MMP1 (Chemicon, Temecula, CA) and anti-MMP13 (Calbiochem) antibodies. Anti-β-actin (AC-15) (Sigma-Aldrich, St Louis, MO, USA) and anti-TIMP1 (Calbiochem) were used as the loading control [36, 37]. Levels of IFI16, casp-1, ASC, and Cdk1 were determined by Western blotting using anti-IFI16 (HPA002134) and anti-casp-1 (HPA003056) (both from Sigma, St. Louis, USA), anti-ASC (AB3607, Merck Millipore, Temecula, CA) and anti-Cdk1/Cdk2 (sc-53219, Santa Cruz Biotechnology, Santa Cruz, CA) antibodies.
Immunofluorescence staining was performed as previously described . Briefly, cSCC cells were fixed with 3% paraformaldehyde and blocked with phosphate buffer saline (PBS) containing 3% bovine serum albumin (BSA). Cells were permeabilized with 0.1% Triton X-100 and labeled with anti-AIM2 antibody (Abnova). Highly cross-adsorbed Alexa Fluor® 568 goat anti-mouse IgG (H+L) (Invitrogen, Carlsbad, CA) was used as a secondary antibody, and Hoechst (H3570; Invitrogen) was used to visualize nuclei. The cells were examined with Zeiss LSM510 Meta confocal microscope (Zeiss, Jena, Germany), and the imaging was performed at the Cell Imaging Core, Turku Centre for Biotechnology, University of Turku and Åbo Akademi University.
Automated immunostaining device (Ventana Medical Systems SA, Illkrich, France) was used to perform IHC of human TMAs and whole tumor sections of OTRs using anti-AIM2 antibody (Sigma, St. Louis, USA), 1:150 . All slides were digitally scanned using a Pannoramic 250 Flash (3DHistech, Budapest, Hungary). AIM2 expression was assessed semiquantitatively by two observers (M.F. and L.N.) as negative (-), weak (+), moderate (++), and strong (+++).
AIM2 knockdown with siRNA
cSCC cells were transfected with two different specific AIM2 siRNAs and control siRNA (75 nM) (Qiagen, Valencia, CA) using the silentFectTM Lipid Reagent (BIO-RAD) . The following sequence was targeted:
AIM2 siRNA_6: 5’-CCCGAAGATCAACACGCT TCA-3’
AIM2 siRNA_5: 5’AAAGGTTAATGTCCCGCT GAA-3’
Control siRNA: 5’-AATTCTCCGAACGTGTCA CGT-3’
Cell viability assay
cSCC cells were transfected with control siRNA and AIM2 siRNAs (75nM). The number of viable cells was determined with WST-1 cell viability reagent (Roche Diagnostics, Mannheim, Germany) 24, 48 and 72 hours after transfection, as described previously  or the number of the cells was determined 72 hours after transfection by counting the cells in 96-well plate wells (n=8).
cSCC cells were transfected with control siRNA and AIM2 siRNAs (75nM). Apoptotic cells were detected 48 hours after transfection with In Situ Cell Death Detection Kit (Roche). Number of TUNEL positive cells was counted from three parallel image fields using 10× objective and compared to total cell number visualized by Hoechst 33342 (Invitrogen).
After transfection with AIM2 or control siRNA cSCC cell were incubated for 24 hours and seeded on ThinCert™ tissue culture inserts coated with collagen type I (Advanced Biomatrix, Fremont, CA) . Nuclei were visualized by Hoechst 33342 (Invitrogen) after 48 hours and counted.
Human cSCC xenografts
Human cSCC xenografts were established as previously . Six-week-old severe combined immunodeficient (SCID) mice (CB17/Icr-Prkdcscid/IcrIcoCrl) (Charles River Laboratories) were randomly allocated into AIM2 (n=8) and control siRNA group (n=8). After 72 hours of transfection of highly tumorigenic cSCC cell line (UT-SCC7) with AIM2 or control siRNA, cSCC cells (5×106) were injected subcutaneously into the back of mice. The size of tumors was measured twice a week and tumor volume was calculated with the formula V = (length × width2)/2 . 21 days after the inoculation tumors were excised, embedded in paraffin and stained with hematoxylin and eosin (H&E). Proliferating cells were detected with anti-Ki-67 antibody (Dako, Glostrup, Denmark). Percentages of Ki-67-positive cells were determined by counting four distinct microscopic fields at 20× magnification (n=7-8). Effect of AIM2 knockdown on vascularization of the xenografts was assessed by IHC with anti-CD34 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) . Blood vessel formation was evaluated in each sample by counting the number of CD34-positive blood vessels in four randomly selected microscopic fields at 20× magnification.
Mann-Whitney U-test and Student’s t-test were used to analyze the significance of difference between groups. Fisher’s exact test was used for analysis of IHC expression level between strong (+++) and moderate (++) expression as one group and weak (+) and absent (-) expression as the other group.
AIM2: absent in melanoma 2;AK: actinic keratosis; ASC: apoptosis-associated speck-like protein containing a caspase recruitment domain; cSCC: cutaneous squamous cell carcinoma; cSCCIS: cSCC in situ; EGF: epidermal growth factor; IFN: interferon; IFI16: interferon-inducible protein 16; IHC: immunohistochemistry; IL: Interleukin; KGF: keratinocyte growth factor; MMP: matrix metalloproteinase; NHEK: normal human epidermal keratinocyte; OTR: organ transplant recipient; qRT-PCR: quantitative real-time PCR; SCID: severe combined immunodeficient; TNF: tumor necrosis factor; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling.
We thank Sari Pitkänen, Johanna Markola, and Sinikka Kollanus for skillful technical assistance and Roel Genders for collecting the histological slides of the Dutch OTR. Jessica Gremmer is thanked for assistance with IHC.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
This study was supported by Turku University Hospital (project 13336), Sigrid Jusélius Foundation, Cancer Research Foundation of Finland, Jane and Aatos Erkko Foundation, and by personal grants to M. F. from Turku Doctoral Program of Clinical Investigation, Finnish Culture Foundation, Cancer Society of Southwestern Finland, Orion-Farmos Research Foundation, Maud Kuistila Foundation, K. Albin Johansson Foundation and Instrumentarium Foundation.
1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002; 146: 1-6.
2. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadiedo JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003; 48: 425-429.
3. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010; 146: 283-287.
4. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 344: 975-983.
5. Kivisaari A, Kähäri VM. Squamous cell carcinoma of the skin: emerging. need for novel biomarkers. World J Clin Oncol. 2013; 4: 85-90.
6. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012; 122: 464-472.
7. Nissinen L, Farshchian M, Riihilä P, Kähäri VM. New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Tissue Res. 2016; 365: 691-702.
8. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003; 348: 1681-1691.
9. Hameetman L, Commandeur S, Bavinck JN, Wisgerhof HC, de Gruijl FR, Willemze R, Mullenders L, Tensen CP, Vrieling H. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. BMC Cancer. 2013; 13: 58.
10. Wisgerhof HC, Edelbroek JR, de Fijter JW, Haasnoot GW, Claas FH, Willemze R, Bavinck JN. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation. 2010; 89: 1231-1238.
11. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012; 481: 278-286.
12. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014; 157: 1013-1022.
13. Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Goss C, Anz D, Simanski M, Glaser R, Harder J, Hornung V, Gallo RL, Ruzicka T, Besch R, Schauber J. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med. 2011; 3: 82ra38.
14. Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015; 265: 6-21.
15. Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. J Invest Dermatol. 2014; 134: 1805-1810.
16. Tervaniemi MH, Katayama S, Skoog T, Siitonen HA, Vuola J, Nuutila K, Sormunen R, Johnsson A, Linnarsson S, Suomela S, Kankuri E, Kere J, Elomaa O. NOD-like receptor signaling and inflammasome-related pathways are highlighted in psoriatic epidermis. Sci Rep. 2016; 6: 22745.
17. Zhang W, Cai Y, Xu W, Yin Z, Gao X, Xiong S. AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation. J Clin Immunol. 2013; 33: 925-937.
18. Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M, Barbacid M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007; 448: 811-815.
19. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006; 72: 1605-1621.
20. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-867.
21. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, Fitzgerald KA. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010; 11: 395-402.
22. de Koning HD, Bergboer JG, van den Bogaard EH, van Vlijmen-Willems IM, Rodijk-Olthuis D, Simon A, Zeeuwen PL, Schalkwijk J. Strong induction of AIM2 expression in human epidermis in acute and chronic inflammatory skin conditions. Exp Dermatol. 2012; 21: 961-964.
23. Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J, Brenner H, Hoffmeister M, Kloor M. Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. Int J Cancer. 2014; 135: 2387-2396.
24. Patsos G, Germann A, Gebert J, Dihlmann S. Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer. 2010; 126: 1838-1849.
25. Chen IF, Ou-Yang F, Hung JY, Liu JC, Wang H, Wang SC, Hou MF, Hortobagyi GN, Hung MC. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Mol Cancer Ther. 2006; 5: 1-7.
26. Ponomareva L, Liu H, Duan X, Dickerson E, Shen H, Panchanathan R, Choubey D. AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Mol Cancer Res. 2013; 11: 1193-1202.
27. Choubey D, Walter S, Geng Y, Xin H. Cytoplasmic localization of the interferon-inducible protein that is encoded by the AIM2 (absent in melanoma) gene from the 200-gene family. FEBS Lett. 2000; 474: 38-42.
28. Ludlow LE, Johnstone RW, Clarke CJ. The HIN-200 family: more than interferon-inducible genes? Exp Cell Res. 2005; 308: 1-17.
29. Ala-aho R, Ahonen M, George SJ, Heikkilä J, Grénman R, Kallajoki M, Kähäri VM. Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene. 2004; 23: 5111-5123.
30. Johansson N, Airola K, Grénman R, Kariniemi AL, Saarialho-Kere U, Kähäri VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol. 1997; 151: 499-508.
31. de Koning HD, van Vlijmen-Willems IM, Zeeuwen PL, Blokx WA, Schalkwijk J. Absent in Melanoma 2 is predominantly present in primary melanoma and primary squamous cell carcinoma, but largely absent in metastases of both tumors. J Am Acad Dermatol. 2014; 71: 1012-1015.
32. Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res. 2017; 5: 94-99.
33. Farshchian M, Nissinen L, Grénman R, Kähäri VM. Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2. Exp Dermatol. 2017; 26: 89-92.
34. Riihilä P, Nissinen L, Farshchian M, Kivisaari A, Ala-aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM. Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2015; 135: 579-588.
35. Riihilä PM, Nissinen LM, Ala-aho R, Kallajoki M, Grenman R, Meri S, Peltonen S, Peltonen J, Kähäri VM. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2014; 134: 498-506.
36. Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Toriseva M, Kivisaari A, Ala-Aho R, Kallajoki M, Veräjänkorva E, Honkanen HK, Heljasvaara R, Pihlajaniemi T, Grénman R, et al. EphB2 promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol. 2015; 135: 1882-1892.
37. Farshchian M, Kivisaari A, Ala-Aho R, Riihilä P, Kallajoki M, Grénman R, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM. Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma. Am J Pathol. 2011; 179: 1110-1119.
38. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986, 31: 229-234.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.